NVG-2089 is under clinical development by Nuvig Therapeutics and currently in Phase I for Bullous Pemphigoid. According to GlobalData, Phase I drugs for Bullous Pemphigoid does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NVG-2089 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NVG-2089 overview
NVG-2089 is under development for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), bullous pemphigoid and severe dermatologic autoimmune disease. It acts by targeting Fc gamma RII-b (FCGRIIB).
Nuvig Therapeutics overview
Nuvig Therapeutics is developing autoimmune therapeutics for the treatment of chronic inflammatory and autoimmune diseases. The company is headquartered in Menlo Park, California, the US.
For a complete picture of NVG-2089’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
